Activities Report and Appendix 4C for June 2022 Quarter
Telix issues Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2022.
ZIRCON Phase III Kidney Cancer Imaging Study Completes Enrolment
Telix Announces a Final Patient Dosed and Recruitment Completed into the Phase III Pivotal ZIRCON Study of TLX250-CDx for Kidney Cancer Imaging
Kevin Richardson Appointed as CEO, Telix Americas
Telix announces that Kevin Richardson will commence in the role of CEO, Telix Americas, on 11 July 2022
Take a PSMA journey with Telix at EAU22
As a specialist in urology, Telix is delighted to invite you onboard the PSMA train. Our symposium, taking place during the EAU Congress 2022, will be an opportunity to ensure your PSMA knowledge is right on track. It’s an exciting field, and the train is moving fast, so join our expert travelers as they take you on a journey towards the latest developments in prostate cancer imaging and treatment.
Presentation to Jefferies Global Healthcare Conference
Telix is pleased to present a webcast of CEO and MD Dr. Christian Behrenbruch presenting at the Jefferies Global Healthcare Conference in New York City on Friday 10 June.
Telix at Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting
Telix is sponsoring a symposium and presenting the company’s prostate cancer imaging agent and clinical programs at #SNMMI22, being held in Vancouver, Canada from 11-14 June, 2022.
Chief Medical Officer, Dr. Colin Hayward, Discussion with Wilsons Advisory
Telix Chief Medical Officer, Dr. Colin Hayward, was hosted this week by Shane Storey, Senior Research Analyst at Wilsons Advisory and Stockbroking Limited, to discuss R&D insights across Telix’s imaging and therapeutic research pipeline.
Telix AGM 2022
Telix's 2022 AGM was held on Wednesday, 18th May 2022 at The Events Centre in Melbourne, Australia.
Telix at ANZSNM Annual Scientific Meeting 2022
Telix is a title partner of the 52nd Australian and New Zealand Society of Nuclear Medicine (ANZSNM) Annual Scientific Meeting (ASM) being held this week in Brisbane, Queensland, 13-15 May.
First Patient Dosed in Phase II Renal Cancer Theranostics Study
Telix announces that a first patient has been dosed in the ‘STARLITE 2’ Phase II study of the Company’s investigational renal cancer therapy at MSK in New York.